137 related articles for article (PubMed ID: 24787379)
1. Screening history of cervical cancers in Emilia-Romagna, Italy: defining priorities to improve cervical cancer screening.
Rossi PG; Caroli S; Mancini S; de' Bianchi PS; Finarelli AC; Naldoni C; Bucchi L; Falcini F;
Eur J Cancer Prev; 2015 Mar; 24(2):128-34. PubMed ID: 24787379
[TBL] [Abstract][Full Text] [Related]
2. [Human Papilloma Virus (HPV), cervical cancer incidence and screening uptake: differences among Northern, Central and Southern Italy].
Giorgi Rossi P; Chini F; Borgia P; Guasticchi G; Carozzi FM; Confortini M; Angeloni C; Buzzoni C; Buonaguro FM;
Epidemiol Prev; 2012; 36(2):108-19. PubMed ID: 22706361
[TBL] [Abstract][Full Text] [Related]
3. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
4. Cervical testing beyond the screening target age - A register-based cohort study from Finland.
Keltto N; Leivonen A; Pankakoski M; Sarkeala T; Heinävaara S; Anttila A
Gynecol Oncol; 2021 Aug; 162(2):315-321. PubMed ID: 34074539
[TBL] [Abstract][Full Text] [Related]
5. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
6. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
[TBL] [Abstract][Full Text] [Related]
7. Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts.
Syrjänen K; Shabalova I; Naud P; Kozachenko V; Derchain S; Zakharchenko S; Roteli-Martins C; Nerovjna R; Longatto-Filho A; Kljukina L; Tatti S; Branovskaja M; Hammes LS; Branca M; Grunjberga V; Erzen M; Sarian LO; Juschenko A; Costa S; Podistov J; Syrjänen S;
Int J Gynecol Cancer; 2009 Jul; 19(5):934-42. PubMed ID: 19574788
[TBL] [Abstract][Full Text] [Related]
8. Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study.
Flores Y; Shah K; Lazcano E; Hernández M; Bishai D; Ferris DG; Lörincz A; Hernández P; Salmerón J;
Salud Publica Mex; 2002; 44(4):335-44. PubMed ID: 12216521
[TBL] [Abstract][Full Text] [Related]
9. Cervical cancer screening and subsequent procedures in women under the age of 25 years between 2007 and 2013 in France: a nationwide French healthcare database study.
Maura G; Chaignot C; Weill A; Alla F; Heard I
Eur J Cancer Prev; 2018 Sep; 27(5):479-485. PubMed ID: 28368950
[TBL] [Abstract][Full Text] [Related]
10. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
[TBL] [Abstract][Full Text] [Related]
11. Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile.
Ferreccio C; Barriga MI; Lagos M; Ibáñez C; Poggi H; González F; Terrazas S; Katki HA; Núñez F; Cartagena J; Van De Wyngard V; Viñales D; Brañes J
Int J Cancer; 2013 Feb; 132(4):916-23. PubMed ID: 22684726
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
13. Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
Liao SY; Rodgers WH; Kauderer J; Bonfiglio TA; Walker JL; Darcy KM; Carter R; Hatae M; Levine L; Spirtos NM; Stanbridge EJ
Int J Cancer; 2009 Nov; 125(10):2434-40. PubMed ID: 19670419
[TBL] [Abstract][Full Text] [Related]
14. Participation in Cervical Screening by Self-collection, Pap, or a Choice of Either in Brazil.
Castle PE; Silva VRS; Consolaro MEL; Kienen N; Bittencourt L; Pelloso SM; Partridge EE; Pierz A; Dartibale CB; Uchimura NS; Scarinci IC
Cancer Prev Res (Phila); 2019 Mar; 12(3):159-170. PubMed ID: 30651294
[TBL] [Abstract][Full Text] [Related]
15. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
[TBL] [Abstract][Full Text] [Related]
16. Changes in the incidence of cervical tumours by disease stage in a cytology-based screening programme.
Bucchi L; Mancini S; Baldacchini F; Giuliani O; Ravaioli A; Vattiato R; Falcini F; Giorgi Rossi P; Campari C; Canuti D; Di Felice E; de Bianchi PS; Ferretti S;
J Med Screen; 2020 Jun; 27(2):96-104. PubMed ID: 31690178
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J;
Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
[TBL] [Abstract][Full Text] [Related]
19. Screening frequency and histologic type influence the efficacy of cervical cancer screening: A nationwide cohort study.
Chiang YC; Chen YY; Hsieh SF; Chiang CJ; You SL; Cheng WF; Lai MS; Chen CA;
Taiwan J Obstet Gynecol; 2017 Aug; 56(4):442-448. PubMed ID: 28805598
[TBL] [Abstract][Full Text] [Related]
20. Screening properties of human papillomavirus testing for predicting cervical intraepithelial neoplasia in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion smears: a prospective study.
Dane C; Batmaz G; Dane B; Cetin A
Ann Diagn Pathol; 2009 Apr; 13(2):73-7. PubMed ID: 19302953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
